Targeting Bcl-2 in CLL

Current Medicinal Chemistry

Volumn 19, Issue 30, 2012, Pages 5109-5115

  Rogalinska M ^a   Kilianska Z M ^a  

^a UNIVERSITY OF LODZ   (Poland)

Author keywords

ABT 263; ABT 737; Antileukemic therapy; Antisense oligonucleotides; BH3 domain mimetics; CLL; Gossypol derivatives; MicroRNA 15a 16 1; Obatoclax; Oblimersen; Small molecular Bcl 2 inhibitors

Indexed keywords

2 AMINO 6 BROMO 4 (1 CYANO 2 ETHOXY 2 OXOETHYL) 4H CHROMENE 3 CARBOXYLIC ACID ETHYL ESTER; 4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; A 779024; ANTIMYCIN A1; ANTINEOPLASTIC AGENT; CARBOPLATIN; DACARBAZINE; FLAVOPIRIDOL; FLUDARABINE; GEMIN X; GOSSYPOL; ISOSORBIDE; LENALIDOMIDE; MICRORNA 15A; MICRORNA 16; N (4 CARBOXYPHENYL)RETINAMIDE; NAVITOCLAX; OBATOCLAX; OBLIMERSEN; PACLITAXEL; PROTEIN BCL 2; RITUXIMAB; SPC 2996; TW 37; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTISENSE THERAPY; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; DOWN REGULATION; DRUG MECHANISM; DRUG POTENTIATION; HUMAN; PROTEIN EXPRESSION; PROTEIN TARGETING; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TRANSCRIPTION REGULATION;

ANTINEOPLASTIC AGENTS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROTO-ONCOGENE PROTEINS C-BCL-2;

EID: 84870418124     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/092986712803530566     Document Type: Review

References (86)

1. Kitada, S.; Andersen, J.; Akar, S.; Zapata, J.M.; Takayama, S.; Krajewski, S.; Wang, H.-G.; Zhang, X.; Bullrich, F.; Croce, C.M.; Rai, K.; Hines, J.; Reed, J.C. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlation with in vitro and in vivo chemoresponses. Blood, 1998, 91, 3379-3389.
2. Einchorst, B.; Dreyling, M.; Robak, T.; Monserrat, E.; Hallek, M. Chronic lymphocytic leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann. Oncol, 2011, 22 suppl. 6, vi 50 - vi 54.
3. Maddocks, K.J.; Lin, T.S. Update in the management of chronic lymphocytic leukemia. J. Hematol. Oncol., 2009, 2, 29 doi; 10.1186/1756-8722-2-29.
4. Reed, J.C.; Pellecchia, M. Apoptosis-based therapies for hematologic malignancies. Blood, 2005, 106, 408-418.
5. Reed, J.C. Bcl-2 family proteins and hematologic malignancies: history and future prospects. Blood, 2008, 111, 3322-3329.
6. Stevenson, F.K.; Caligarias-Cappio, F. Chronic lymphocytic leukemia: revelations from the B-cell receptor. Blood, 2004, 103, 4389-4395.
7. Messmer, B.T.; Messmer, D.; Allen, S.L.; Kolitz, J.E.; Kudalkar, P.; Cesar, D.; Murphy, E.J.; Koduru, P.; Ferrarini, M.; Zupo, S.; Cutrona, G.; Damle, R.; Wasil, T.; Rai, K.R.; Hellerstein, M.K.; Chiorazzi, N. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J. Clin. Invest., 2005, 115, 755-764.
8. Sieklucka, M.; Pozarowski, P.; Bojarska-Junak, A.; Hus, I.; Dmoszyńska, A.; Roliński, J. Apoptosis in B-CLL: The relationship between higher ex vivo spontanous apoptosis before treatment in III-IV Rai stage patients and poor outcome. Oncol. Rep., 2008, 19, 1611-1620.
9. Pepper, C.; Lin, T.T.; Pratt, G.; Hewamana, S.; Brennan, P.; Hiller, L.; Hills, R.; Ward, R.; Starczynski, J.; Austen, B.; Hooper, L.; Stankovic, T.; Fegan, C. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood, 2008, 112, 3538-3540.
10. Marzo, I.; Perez-Galan, P.; Giraldo, P.; Rubio-Felix, D.; Anel, A.; Naval, J. Cladribine induces apoptosis in human leukaemia cells by caspase-dependent and -independent pathways acting on mitochondria. Biochem. J., 2001, 35, 537-546.
11. Green, D.R.; Evan, G.J. A matter of life and death. Cancer Cell, 2002, 1, 19-30.
12. Daniel, D.R. Bcl-2 family proteins: critical checkpoints of apoptotic cell death. Clin. Cancer Res., 2007, 13, 7254-7263.
13. Buggins, A.G.S.; Pepper, C.J. The role of Bcl-2 family proteins in chronic lymphocyticleukemia. Leuk. Res., 2010, 34, 837-842.
14. Chipuk, J.E.; Moldovenau, T.; Llambi, F.; Parsons, M.J.; Green, D.R. The Bcl-2 family reunion. Mol. Cell., 2010, 37, 299-310.
15. Borner, C. The Bcl-2 protein family: Sensor and checkpoints for life - or death decision. Mol. Immunol., 2003, 39, 615-647.
16. Kitada, S.; Andersen, J.; Akar, S.; Zapata, J.M.; Takayama, S.; Krajewski, S.; Wang, H.G.; Zhang, X.; Bullrich, F.; Croce, C.M.; Rai, K.; Hines, J.; Reed, J.C. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlation with in vitro and in vivo chemoresponses. Blood, 1998, 91, 3379-3389.
17. Johnston, J.B.; Paul, J.T.; Neufeld, N.J.; Haney, N.; Kropp, D.M.; Hu, X.; Cheang, M.; Gibson, S.B. Role of myeloid cell factor-1 (Mcl-1) in chronic lymphocytic leukemia. Leuk. Lymph., 2004, 45, 2017-2027.
18. Żołnierczyk, J.D.; Komina, O.; Błoński, J.Z.; Borowiak, A; Cebula-Obrzut, B.; Smolewski, P.; Robak, T.; Kiliańska, Z.M.; Wȩsierska-Ga̧dek, J. Can ex vivo evaluation (testing) predict the sensitivity of CLL cells to therapy with purine analogs In conjunction with an alkylating agent? A comparison of in vivo and ex vivo responses to treatment. Med. Oncol., 2011, Nov. 16 [Epub ahead of print].
19. Droin, N.M.; Green, D.R. Role of Bcl-2 family members in immunity and disease. Biochim. Biophys. Acta, 2004, 1644, 179-188.
20. Kelly, P.N.; Strasser, A. The role of Bcl-2 and its pro-survival relatives In tumorigenesis and cancer therapy. Cell Death Differ., 2011, 18, 1414-1424.
21. Skommer, J.; Brittain, T.; Raychaudhuri, S. Bcl-2 inhibits apoptosis by increasing the time-to-death and intrinsic cell-to-cell variations in the mitochondrial pathway of cell death. Apoptosis, 2010, 15, 1223-1233.
22. Kabore, A.F., Johnson, J.B., Gibson, S.B., Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications. Curr. Cancer Drug Tergets, 2004, 4, 147-163.
23. Call, J.A.; Gail Eckhardt, S.; Ross Camidge, D. Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol., 2008, 9, 1002-1011.
24. Stein, C.A; Benimetskaya, L.; Mani, S. Antisense strategies for oncogene inactivation. Semin. Oncol., 2005, 32, 563-572.
25. Tamm, I. Antisense therapy in malignant disease: status quo and quo vadis? Clin. Sci., 2006, 110, 427-442.
26. Emi, M.; Kim, R.; Tanabe, K.; Uchida, Y., Toge, T. Targeted therapy against BCL-2-related proteins in breast cancer cells. Breast Cancer Res., 2005, 7, R940-952.
27. Jahrsdörfer, B.; Jox, R.; Mühlenhoff, L.; Tschoep, K.; Krug, A.; Rothenfusser, S.; Meinhardt, G.; Emmerich, B.; Endres, S.; Hartmann, G. Modulation of malignant B cell activation and apoptosis by bcl-2 antisense ODN and immunostimulatory CpG ODN. J. Leukoc. Biol., 2002, 72, 83-92.
28. Kim, R.; Emi, M.; Matsuura, K.; Tanabe, K. Antisense and non antisense effects of antisense Bcl-2 on multiple roles of Bcl-2 as a chemosensitizer in cancer therapy. Cancer Gene Ther., 2007, 14, 1-11.
29. Zou, W.; Machelon, V.; Coulomb-L'Hermin, A.; Borvak, J.; Nome, F.; Isaeva, T.; Wei, S,; Krzysiek, R.; Durand-Gasselin, I.; Gordon, A,; Pustilnik, T.; Curiel, D.T.; Galanaud, P.; Capron, F.; Emilie, D.; Curiel, T.J. Stromalderived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells. Nat. Med. 2001, 7, 1339-1346.
30. Advani, P.P.; Paulus, A.; Masood, A.; Sher, T.; Chanan-Khan, A. Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia. Expert Opin. Drug Metab. Toxicol., 2011, 7, 765-774.
31. Cheson, B.D.; Oblimersen for the treatment of patients with chronic lymphocytic leukemia. Ther. Clin. Risk Manag., 2007, 3, 855-870.
32. O'Brien, S.; Moore, J.; Boyd, T.E.; Larrat, L.M.; Skotnicki, A.; Koziner, B.; Chanan-Khan, A.A.; Seymour, J.F.; Bociek, R.G.; Pavletic, S.; Rai, K.R. Randomised phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol., 2007, 25, 1114-11120.
33. Schwartz, P.S.; Hockenberry, D.M. Bcl-2-related survival proteins. Cell Death Differ., 2006, 13, 1250-1255.
34. Reed, J.C.; Pellecchia, M. Apoptosis-based therapies for hematologic malignancies. Blood, 2005, 106, 408-418.
35. O'Brien, S.; Moore, J.O.; Boyd, T.E.; Larratt, L.M.; Skotnicki, A.; Koziner, B.; Chanan-Khan, A.A.; Seymour, J.F.; Bociek, R.G.; Pavletic, S.; Rai, K.R. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. J. Clin. Oncol., 2007, 25, 1114-1120.
36. Kang, M.H.; Reynolds, C.P. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin. Cancer Res., 2009, 15, 1126-1132.
37. Dürig, J.; Dührsen, U.; Klein-Hitpass, L.; Worm, J.; Hansen, J.B.; Ørum, H.; Wissenbach, M. The novel antisense Bcl-2 inhibitor SPC2996 causes rapid leukemic cell clearance and immune activation in chronic lymphocytic leukemia. Leukemia, 2011, 25, 638-647.
38. Nguyen, M.; Marcellus, R.C.; Roulston, A.; Watson, M.; Serfass, L.; Murthy Madiraju, S.R.; Goulet, D.; Viallet, J.; Bélec, L.; Billot, X.; Acoca, S.; Purisima, E.; Wiegmans, A.; Cluse, L.; Johnstone, R.W.; Beauparlant, P.; Shore, G.C. Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 19512-19517.
39. Capitani, N.; Baldari, C.T. The Bcl-2 family as a rational target for the treatment of B-cell chronic lymphocytic leukemia. Curr. Med. Chem., 2010, 17, 801-811.
40. Shore, G.C.; Viallet, J. Modulating the Bcl-2 family of apoptosis supressors for potential therapeutic benefit in cancer. Hematol. Am. Soc. Hematol. Educ. Program, 2005, 226-230.
41. Campas, C.; Cosialls, A.M.; Barragan, M.; Iglesias-Serret, D.; Santidrián, A.F.; Coll-Mulet, L.; de Frias, M.; Domingo, A.; Pons, G.; Gil, J. Bcl-2 inhibitors induce apoptosis in chronic lymphocytic leukemia cells. Exp. Hematol., 2006, 34, 1663-1669.
42. Pérez-Galán, P.; Roué, G.; López-Guerra, M.; Nguyen, M.; Villamor, N.; Montserrat, E.; Shore, G.C.; Campo, E.; Colomer, D. BCL-2 phosphorylation modulates sensitivity to the BH3 mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic leukemia cells. Leukemia, 2008, 22, 1712-1720.
43. O'Brien, S.M.; Claxton, D.F.; Crump, M.; Faderl, S.; Kipps, T.; Keating, M.J.; Viallet, J.; Cheson, B.D. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. Blood, 2009, 113, 299-305.
44. Petros, A.M.; Olejniczak, E.T.; Fesik, S.W. Structural biology of the Bcl-2 family of proteins. Biochim. Biophys. Acta, 2004, 1664, 83-94.
45. Balakrishnan, K.; Wierda, W.G.; Keating, M.J.; Gandhi, V. Gossypol, a BH3 mimetic, induces apoptosis in chronic lymphocytic leukemia cells. Blood, 2008, 112, 1971-1980.
46. Carballido, E.; Veliz, M.; Komrokji, R.; Pinilla-Ibarz, J. Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia. Cancer Control., 2012, 19, 54-67.
47. Wang, Y.; Rao, P.N. Effect of gossypol on DNA synthesis and cell cycle progression of mammalian cells in vitro. Cancer Res., 1984, 44, 35-38.
48. Zhang, M.; Liu, H.; Guo, R.; Ling, Y.; Wu, X.; Li, B.; Roller, P.P.; Wang, S.; Yang, D. Molecular mechanism of gossypol-induced cell growth inhibition and cell death of HT-29 human colon carcinoma cells. Biochem. Pharmacol., 2003, 66, 93-103.
49. Huang, Y.W.; Wang, L.S.; Dowd, M.K.; Wan, P.J.; Lin; Y.C. (-)-Gossypol reduces invasiveness in metastatic prostate cancer cells. Anticancer Res., 2009, 29, 2179-2188.
50. Huang, Y.W.; Wang, L.S.; Chang, H.L.; Ye, W.; Sugimoto, Y.; Dowd, M.K.; Wan, P.J.; Lin, Y.C. Effects of serum on (-) gossypol-suppressed growth in human prostate cancer cells. Anticancer Res., 2006, 26, 3613-3620.
51. Jarvis, W.D.; Turner, A.J.; Povirk, L.F.; Traylor, R.S.; Grant, S. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res., 1994, 54, 1707-1714.
52. Huang, L.H.; Hu, J.Q.; Tao, W.Q.; Li, Y.H.; Li, G.M.; Xie, P.Y.; Liu, X.S.; Jiang, J. Gossypol inhibits phosphorylation of Bcl-2 in human leukemia HL- 60 cells. Eur. J. Pharmacol., 2010, 645, 9-13.
53. Lei, X.; Chen, Y.; Du, G.; Yu, W.; Wang, X.; Qu, H.; Xia, B.; He, H.; Mao, J.; Zong, W.; Liao, X.; Mehrpour, M.; Hao, X.; Chen, Q. Gossypol induces Bax/Bak-independent activation of apoptosis and cytochrome c release via conformational change in Bcl-2. FASEB J., 2006, 20, 2147-2149.
54. Zhang, M.; Liu, H.; Tian, Z.; Griffith, B.N.; Ji, M.; Li, Q.Q. Gossypol induces apoptosis in human PC-3 prostate cancer cells by modulating caspasedependent and caspase-independent cell death pathways. Life Sci., 2007, 80, 767-774.
55. Paoluzzi, L.; Gonen, M.; Bhagat, G.; Furman, R.R.; Gardner, J.R.; Scotto, L.; Gueorguiev, M.L.; Heaney, M.L.; Manova, K.; O'Connor, O.A. The BH3- only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies. Blood, 2008, 112, 2906-2916.
56. Tse, C.; Shoemaker, A.R.; Adickes, J.; Anderson, M.G.; Chen, J.; Jin, S.; Johnson, E.F.; Marsh, K.C.; Mitten, M.J.; Nimmer, P.; Roberts, L.; Tahir, S.K.; Xiao, Y.; Yang, X.; Zhang, H.; Fesik, S.; Rosenberg, S.H.; Elmore, S.W. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res., 2008, 68, 3421-3428.
57. Balakrishnan, K.; Burger, J.A.; Wierda, W.G.; Gandhi, V. AT-101 induces apoptosis in CLL B cells and overcomes stromal cell-mediated Mcl-1 induction and drug resistance. Blood, 2009,113, 149-153.
58. Masood, A.; Chitta, K.; Paulus, A.; Khan, A.N.; Sher, T.; Ersing, N.; Miller, K.C.; Manfredi, D.; Ailawadhi, S.; Borrelo, I.; Lee, K.P.; Chanan-Khan, A. Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. Br. J. Haematol., 2011, doi: 10.1111/j.1365-2141.2011.08984.x.
59. Konopleva, M.; Contractor, R.; Tsao, T.; Samudio, I.; Ruvolo, P.P.; Kitada, S.; Deng, X.; Zhai, D.; Shi, Y.X.; Sneed, T.; Verhaegen, M.; Soengas, M.; Ruvolo, V.R.; McQueen, T.; Schober, W.D.; Watt, J.C.; Jiffar, T.; Ling, X.; Marini, F.C.; Harris, D.; Dietrich, M.; Estrov, Z.; McCubrey, J.; May, W.S.; Reed, J.C.; Andreeff, M. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell, 2006, 10, 375-388.
60. Chauhan, D.; Velankar, M.; Brahmandam, M.; Hideshima, T.; Podar, K.; Richardson, P.; Schlossman, R.; Ghobrial, I.; Raje, N.; Munshi, N.; Anderson, K.C. A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. Oncogene, 2006, 26, 2374-2380.
61. Del GaizoMoore, V.; Brown, J.R.; Certo, M.; Love, T.M.; Novina, C.D.; Letai, A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J. Clin. Invest., 2007, 117, 112-121.
62. Tahir, S.K.; Yang, X.; Anderson, M.G.; Morgan-Lappe, S.E.; Sarthy, A.V.; Chen, J.; Warner, R.B.; Ng, S.C.; Fesik, S.W.; Elmore, S.W.; Rosenberg, S.H.; Tse, C. Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. Cancer Res., 2007, 67, 1176-1183.
63. Lin, X.; Morgan-Lappe, S.; Huang, X.; Li, L.; Zakula, D.M.; Vernetti, L.A.; Fesik, S.W.; Shen, Y. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-X(L) inhibitor ABT-737. Oncogene, 2007, 26, 3972-3979.
64. Rosato, R.R.; Almenara, J.A.; Kolla, S.S.; Maggio, S.C.; Coe, S.; Giménez, M.S.; Dent, P.; Grant, S. Mechanismand functional role of XIAP and Mcl-1 downregulation in flavopiridol/vorinostat antileukemic interactions. Mol. Cancer Ther., 2007, 6, 692-702.
65. Morales, M.C.; Pérez-Yarza, G.; Nieto-Rementeria, N.; Boyano, M.D.; Jangi, M.; Atencia, R.; Asumendi, A. Intracellular glutathione levels determine cell sensitivity to apoptosis induced by the antineoplasic agent N-(4-hydroxyphenyl) retinamide. Anticancer Res, 2005, 25, 1945-1951.
66. Roberts, A.W.; Seymour, J.F.; Brown, J.R.; Wierda, W.G.; Kipps, T.J.; Khaw, S.L.; Carney, D.A.; He, S.Z.; Huang, D.C.; Xiong, H.; Cui, Y.; Busman, T.A.; McKeegan, E.M.; Krivoshik, A.P.; Enschede, S.H.; Humerickhouse, R. Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease. J Clin Oncol., 2011, doi: 10.1200/JCO.2011.34.7898.
67. Lin, T. New agents in chronic lymphocytic leukemia. Curr. Hematol. Malig. Rep., 2010, 5, 29-34.
68. Chen, J.; Freeman, A.; Liu, J.; Dai, Q.; Lee, R.M. The apoptotic effect of HA14-1, a Bcl-2-interacting small molecular compound, requires Bax translocation and is enhanced by PK11195. Mol. Cancer Ther., 2002; 1, 961-967.
69. Lickliter, J.D.; Wood, N.J.; Johnson, L.; McHugh, G.; Tan, J.; Wood, F.; Cox, J.; Wickham, N.W. HA14-1 selectively induces apoptosis in Bcl-2-overexpressing leukemia/lymphoma cells, and enhances cytarabine-induced cell death. Leukemia, 2003, 17, 2074-2080.
70. An, J.; Chen, Y.; Huang, Z. Critical upstream signals of cytochrome C release induced by a novel Bcl-2 inhibitor. J. Biol. Chem., 2004, 279, 19133-19140.
71. Sinicrope, F.A.; Penington, R.C.; Tang, X.M. Tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis is inhibited by Bcl-2 but restored by the small molecule Bcl-2 inhibitor, HA 14-1, in human colon cancer cells. Clin. Cancer Res., 2004, 10, 8284-8292.
72. Reiners, J.J.; Jr, Kessel, D. Susceptibility of myelomonocytic leukemia U937 cells to the induction of apoptosis by the non-peptidic Bcl-2 ligand HA14-1 is cell cycle phase-dependent. Cancer Lett., 2005, 221, 153-163.
73. Park, W.H.; Han,Y.W.; Kim, S.H.; Kim, S.Z. An ROS generator, antimycin A, inhibits the growth of HeLa cells via apoptosis. J. Cell. Biochem., 2007, 102, 98-109.
74. Wang, G.; Nikolovska-Coleska, Z.; Yang, C.Y.; Wang, R.; Tang, G.; Guo, J.; Shangary, S.; Qiu, S.; Gaor, W.; Yang, D.; Meagher, J.; Stuckey, J.; Krajewski, K.; Jiang, S.; Roller, P.P.; Abaan, H.O.; Tomita, Y.; Wang, S. Structure based design of potent small-molecule inhibitors of antiapoptotic Bcl-2 proteins. J. Med. Chem., 2006, 49, 6139-6142.
75. Al-Katib, A.M.; Sun, Y.; Goustin, A.S.; Azmi, A.S.; Chen, B.; Aboukameel, A.; Mohammad, R.M. SMI of Bcl-2 TW-37 is active across a spectrum of Bcell tumors irrespective of their proliferative and differentiation status. J. Hematol. Oncol., 2009, 2:8.
76. Calin, G.A.; Liu, C.; Sevignani, C.; Ferracin, M.; Felli, N.; Dumitru, C.D.; Shimizu, M.; Cimmino, A.; Zupo, S.; Dono, M.; Dell'Aquila, M.L.; Alder, H.; Rassenti, L.; Kipps, T.J.; Bullrich, F.; Negrini, M.; Croce, C.M. MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc. Nat. Acad. Sci. USA, 2004, 32, 11755-11760.
77. Nicoloso, M.S.; Kipps, T.J.; Croce, M.C.; Calin, G.A. MicroRNAs in the pathogeny of chronic lymphocytic leukemia. British J. Haematol., 2007, 139, 709-716.
78. Nana-Sinkam, S.P.; Croce, C.M. MicroRNA in chronic lymphocytic leukemia: transitioning from laboratory-based investigation to clinical application. Cancer Gen. Cytogen., 2010, 203, 127-133.
79. Pekarsky, Y.; Zanesi, N.; Croce, C.M. Molecular basis of CLL. Seminars in Cancer Biology, 2010, 20, 370-376.
80. Farazi, T.A.; Spitzer, J.I.; Morozov, P.; Tuschl, T. miRNAs in human cancer. Journal of Patology, 2011, 223, 102-115.
81. Calin, G.A.; Dumitru, C.D.; Schimizu, M., Bichi, R., Zupo, S., Noch, E., Aldler, H., Rattan, S., Keating, M., Rai, K., Rassenti, L., Kipps, T., Negrini, M., Bullrich, F., Croce, CM. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Nat. Acad. Sci. USA, 2002, 99, 15524-15529.
82. Calin, G.A.; Ferracin, M.; Cimmino, A.; Di Leva, G.; Shimizu, M.; Wójcik, S.E.; V.lorio, M.; Visone, R.; Sever, N.; Fabbri, M.; Iuliano, R.; Palumbo, T.; Pichiorri, F.; Roldo, C.; Garzon, R.; Sevignani, C.; Rassenti, L.; Alder, H.; Volinia, S.; Liu, C.; Kipps, T.J.; Negrini, M.; Croce, C.M. A microRNA signature associated with prognosis and progression in chronic lymphatic leukemia. N. Engl. J. Med., 2005, 353, 1793-1801.
83. Cimmino, A.; Calin, G.A.; Fabbri, M.; Lorio, M. V.; Ferracin, M.; Shimizu, M.; Wójcik, S.E.; Aqeilan, R.I.; Zupo, S.; Dono, M.; Rassenti, L.; Alder, H.; Volinia, S.;Liu, C.; Kipps, T.J.; Negrini, M.; Croce, C.M. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc. Nat. Acad. Sci. USA, 2005, 102, 13944-13949.
84. Aqeilan, R.I.; Calin, G.A.; Croce, C.M. miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ., 2010, 17, 215-220.
85. Fulci, V.; Chiaretti, S.; Goldoni, M.; Azzalin, G.; Carucci, N.; Tavolaro, S.; Castellano, L.; Magrelli, A.; Citarella, F.; Messina, M.; Maggio, R.; Peragine, N.; Santangelo, S.; Mauro, F.R.; Langraf, P.; Tuschl, T.; Weir, D.B.; Chien, M.; Russo, J.J.; Ju, J.; Sheridan, R.; Sander, C.; Zavolan, M.; Guarini, A.; Foa, R.; Macino, G. Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood, 2007, 109, 4944-4951.
86. Calin, G.A.; Cimmino, A.; Fabbri, M.; Ferracin, M.; Wójcik, S.E., Shimizu, M.; Taccioli, C.; Zanesi, N.; Garzon, R.; Aqeilan, R.I.; Alder, H.; Volinia, S.; Rassenti, L.; Liu, X.; Liu, C.; Kipps, T.J.; Negrini, M.; Croce, C.M. Mir-15a and miR-16-1 cluster functions in human leukemia. Proc. Nat. Acad. Sci. USA, 2008, 105, 5166-5171.